CD33 and myelodysplastic syndrome: Secondly, clinical trials have demonstrated the feasibility, safety, and efficacy of autologous CD33-directed CAR-T therapy, showing promising results in targeting relapsed/refractory AML in both pediatric and adult populations, as well as high-risk MDS in elderly individuals30–33.